Ligand Pharmaceuticals (LGND) News Today $106.59 +2.32 (+2.22%) As of 04/14/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period Ligand Pharmaceuticals (NASDAQ:LGND) Stock Rating Upgraded by StockNews.comApril 15 at 1:43 AM | americanbankingnews.comLigand Pharmaceuticals Incorporated (NASDAQ:LGND) Shares Sold by Russell Investments Group Ltd.Russell Investments Group Ltd. reduced its position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Free Report) by 17.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 95,600 shares of the biotechnology company's stockApril 14 at 4:30 AM | marketbeat.comLigand Pharmaceuticals (NASDAQ:LGND) Earns Buy Rating from Analysts at Stifel NicolausStifel Nicolaus started coverage on Ligand Pharmaceuticals in a research report on Thursday. They set a "buy" rating and a $143.00 target price for the company.April 12 at 9:44 AM | marketbeat.comF M Investments LLC Cuts Stake in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)F M Investments LLC reduced its stake in shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Free Report) by 60.6% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 52,883 shares of the biotechnologApril 12 at 7:23 AM | marketbeat.comCenterBook Partners LP Trims Holdings in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)CenterBook Partners LP lessened its stake in shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Free Report) by 53.8% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 23,539 shares of the biotechnologyApril 12 at 7:09 AM | marketbeat.comNorges Bank Makes New Investment in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)Norges Bank purchased a new position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 46,290 shares of the biotechnology company's stock, valued at approximately $4,960,000. NoApril 12 at 4:02 AM | marketbeat.comLigand initiated with a Buy at StifelApril 11, 2025 | markets.businessinsider.comStifel Initiates Coverage of Ligand Pharmaceuticals (LGND) with Buy RecommendationApril 11, 2025 | msn.comThis Ligand Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For ThursdayApril 10, 2025 | benzinga.comLigand Pharmaceuticals (NASDAQ:LGND) Cut to Sell at StockNews.comStockNews.com downgraded shares of Ligand Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Monday.April 9, 2025 | marketbeat.comMassachusetts Financial Services Co. MA Takes Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)Massachusetts Financial Services Co. MA bought a new position in shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 276,731 shares of the biotechnApril 8, 2025 | marketbeat.comFranklin Resources Inc. Purchases 90,743 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)Franklin Resources Inc. boosted its holdings in shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Free Report) by 95.9% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm owned 185,402 shares of the biotechnology company's stock after buying an additiApril 8, 2025 | marketbeat.comVanguard Group Inc. Buys 115,005 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)Vanguard Group Inc. increased its stake in shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Free Report) by 5.8% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 2,085,627 shares of the biotecApril 7, 2025 | marketbeat.com3,900 Shares in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Acquired by KLP Kapitalforvaltning ASKLP Kapitalforvaltning AS purchased a new stake in shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Free Report) during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 3,900 shares of the biotechnology company's sApril 6, 2025 | marketbeat.comLigand Pharmaceuticals Incorporated (NASDAQ:LGND) Short Interest UpdateLigand Pharmaceuticals Incorporated (NASDAQ:LGND - Get Free Report) saw a large increase in short interest in March. As of March 15th, there was short interest totalling 955,100 shares, an increase of 22.4% from the February 28th total of 780,100 shares. Based on an average daily trading volume, of 115,100 shares, the days-to-cover ratio is currently 8.3 days. Currently, 5.4% of the company's shares are sold short.April 4, 2025 | marketbeat.comRaymond James Financial Inc. Makes New $2.34 Million Investment in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)Raymond James Financial Inc. acquired a new position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 21,830 shares of the biotechnologyMarch 30, 2025 | marketbeat.comLoomis Sayles & Co. L P Purchases 24,921 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)Loomis Sayles & Co. L P raised its position in shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Free Report) by 6.7% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 397,700 shares of the biotechnologMarch 29, 2025 | marketbeat.comVirtu Financial LLC Takes $338,000 Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)Virtu Financial LLC acquired a new position in shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm acquired 3,155 shares of the biotechnology coMarch 29, 2025 | marketbeat.comLigand Pharmaceuticals Incorporated (NASDAQ:LGND) Receives Consensus Recommendation of "Buy" from AnalystsShares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Get Free Report) have been given a consensus recommendation of "Buy" by the six ratings firms that are covering the company, Marketbeat.com reports. Six investment analysts have rated the stock with a buy rating. The average 1-year priceMarch 27, 2025 | marketbeat.comCongress Wealth Management LLC DE Purchases 4,014 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)Congress Wealth Management LLC DE lifted its position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Free Report) by 4.4% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 94,335 sharMarch 25, 2025 | marketbeat.com4,418 Shares in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Purchased by Summit Global InvestmentsSummit Global Investments acquired a new stake in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund acquired 4,418 shares of the biotechnology companMarch 25, 2025 | marketbeat.comRoyce & Associates LP Sells 3,193 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)Royce & Associates LP trimmed its holdings in shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Free Report) by 52.4% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 2,897 shares of the biotechnology company's stock afterMarch 23, 2025 | marketbeat.comCharles Schwab Investment Management Inc. Increases Stock Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)Charles Schwab Investment Management Inc. boosted its stake in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Free Report) by 4.0% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 170,419March 20, 2025 | marketbeat.comConnor Clark & Lunn Investment Management Ltd. Sells 3,200 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)Connor Clark & Lunn Investment Management Ltd. reduced its position in shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Free Report) by 11.9% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 23,763 sharesMarch 19, 2025 | marketbeat.comLigand Pharmaceuticals Incorporated (NASDAQ:LGND) Shares Acquired by AmundiAmundi boosted its holdings in shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Free Report) by 196.9% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 9,548 shares of the biotechnology company'sMarch 19, 2025 | marketbeat.comLigand Pharmaceuticals (NASDAQ:LGND) Rating Increased to Hold at StockNews.comStockNews.com raised Ligand Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Tuesday.March 18, 2025 | marketbeat.comBank of New York Mellon Corp Sells 4,847 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)Bank of New York Mellon Corp lowered its stake in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Free Report) by 3.6% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 129,992 sharesMarch 13, 2025 | marketbeat.comCallan Family Office LLC Takes Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)Callan Family Office LLC acquired a new stake in shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 2,438 shares of the biotechnoMarch 12, 2025 | marketbeat.comLigand Pharmaceuticals (NASDAQ:LGND) Downgraded by StockNews.com to "Sell"StockNews.com lowered shares of Ligand Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Monday.March 11, 2025 | marketbeat.comBarclays Keeps Their Buy Rating on Ligand Pharma (LGND)March 10, 2025 | markets.businessinsider.comEssex Investment Management Co. LLC Sells 3,901 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)Essex Investment Management Co. LLC lowered its stake in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Free Report) by 5.6% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 65,247 shares of the biotechnology company'sMarch 10, 2025 | marketbeat.comLisanti Capital Growth LLC Has $4.18 Million Holdings in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)Lisanti Capital Growth LLC boosted its holdings in shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Free Report) by 57.4% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 39,010 shares of the biotechnology company's sMarch 8, 2025 | marketbeat.comOctavio Espinoza Sells 5,000 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) StockLigand Pharmaceuticals Incorporated (NASDAQ:LGND - Get Free Report) CFO Octavio Espinoza sold 5,000 shares of Ligand Pharmaceuticals stock in a transaction on Tuesday, March 4th. The stock was sold at an average price of $115.03, for a total transaction of $575,150.00. Following the completion of the transaction, the chief financial officer now directly owns 18,879 shares in the company, valued at approximately $2,171,651.37. The trade was a 20.94 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.March 7, 2025 | marketbeat.comLigand Pharmaceuticals Incorporated (NASDAQ:LGND) CFO Sells $575,150.00 in StockMarch 7, 2025 | insidertrades.comDana Investment Advisors Inc. Sells 4,373 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)Dana Investment Advisors Inc. lessened its position in shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Free Report) by 5.4% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 76,229 shares of the biotechnolMarch 6, 2025 | marketbeat.comCookson Peirce & Co. Inc. Purchases 2,755 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)Cookson Peirce & Co. Inc. grew its position in shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Free Report) by 56.3% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 7,650 shares of the biotechnoMarch 6, 2025 | marketbeat.comFisher Asset Management LLC Increases Stake in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)Fisher Asset Management LLC increased its position in shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Free Report) by 68.9% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 100,638 shares of the biotecMarch 5, 2025 | marketbeat.comLigand Pharmaceuticals (NASDAQ:LGND) Trading Down 8.8% - Here's WhyLigand Pharmaceuticals (NASDAQ:LGND) Trading Down 8.8% - What's Next?March 4, 2025 | marketbeat.comLGND: First Steps into Cell & Gene TherapyMarch 3, 2025 | msn.comLigand Pharma (LGND) Receives a Buy from RBC CapitalMarch 3, 2025 | markets.businessinsider.comLigand to Participate in March Investor ConferencesMarch 3, 2025 | globenewswire.comLigand Pharmaceuticals Incorporated (NASDAQ:LGND) Given Average Recommendation of "Buy" by BrokeragesLigand Pharmaceuticals Incorporated (NASDAQ:LGND - Get Free Report) has been given an average rating of "Buy" by the six analysts that are presently covering the stock, Marketbeat reports. Six analysts have rated the stock with a buy recommendation. The average twelve-month target price among brokMarch 2, 2025 | marketbeat.comPrincipal Financial Group Inc. Purchases 6,382 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)Principal Financial Group Inc. raised its holdings in shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Free Report) by 6.8% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 99,590 shares of the biotechnoMarch 1, 2025 | marketbeat.comLigand Pharmaceuticals (NASDAQ:LGND) Trading Up 7.3% - Should You Buy?Ligand Pharmaceuticals (NASDAQ:LGND) Shares Up 7.3% - Here's What HappenedFebruary 28, 2025 | marketbeat.comLigand Pharmaceuticals (NASDAQ:LGND) Releases Quarterly Earnings ResultsLigand Pharmaceuticals (NASDAQ:LGND - Get Free Report) posted its quarterly earnings results on Thursday. The biotechnology company reported ($1.64) earnings per share for the quarter, missing analysts' consensus estimates of $1.37 by ($3.01). Ligand Pharmaceuticals had a return on equity of 4.95% and a net margin of 29.68%.February 28, 2025 | marketbeat.comLigand Pharmaceuticals Incorporated (LGND) Q4 2024 Earnings Call TranscriptFebruary 28, 2025 | seekingalpha.comOppenheimer Sticks to Their Buy Rating for Ligand Pharma (LGND)February 28, 2025 | markets.businessinsider.comLigand Pharmaceuticals Incorporated (NASDAQ:LGND) Q4 2024 Earnings Call TranscriptFebruary 28, 2025 | insidermonkey.comLigand Pharmaceuticals (NASDAQ:LGND) Issues FY 2025 Earnings GuidanceLigand Pharmaceuticals (NASDAQ:LGND) updated its FY 2025 earnings guidance. The company provided EPS guidance of 6.000-6.250 for the period, compared to the consensus estimate of 6.140. The company also issued revenue guidance of $180.0 millionillion-$200.0 millionillion, compared to the consensus estimate of $188.8 millionillion.February 28, 2025 | marketbeat.comLigand Pharmaceuticals Inc (LGND) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and ...February 28, 2025 | finance.yahoo.com Remove Ads Get Ligand Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for LGND and its competitors with MarketBeat's FREE daily newsletter. Email Address LGND Media Mentions By Week LGND Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. LGND News Sentiment▼1.100.80▲Average Medical News Sentiment LGND News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. LGND Articles This Week▼135▲LGND Articles Average Week Remove Ads Get Ligand Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for LGND and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies HALO News Today MDGL News Today RGEN News Today ALKS News Today IONS News Today FOLD News Today DVAX News Today MNKD News Today BCRX News Today INVA News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:LGND) was last updated on 4/15/2025 by MarketBeat.com Staff From Our PartnersGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredDOGE tax surpriseElon Musk's DOGE agents have some very strange plans for the IRS... Recently, it emerged that our tax auth...Altimetry | SponsoredAmazon ShockerJeff Bezos quietly backing world-changing tech (not AI) The Amazon founder is quietly advancing a radical t...Stansberry Research | SponsoredCaught on Camera: Elon Musk’s “Area 51”You won’t believe what tech legend Jeff Brown found in what he calls Elon Musk’s “Area 51.” (Click here to see...Brownstone Research | SponsoredThree new patents reveal Elon and Trump’s secret “Project America”Right now for a limited time… You can get Tim Bohen’s top 5 Trump stocks for 2025… For only ONE DOLLAR!...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ligand Pharmaceuticals Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Share Ligand Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy LGND Stock Free LGND Stock Alerts